CI

At a glance

ClinicalIndex Comparison Record
Phase 4Active· 43 enrolled
Drug / intervention
olaparib +3 moredrug
Likely dose
olaparib 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05457257
NCT05457257Phase 4Active
CompareCT.gov

A Randomized, Open-label Study to Assess the Efficacy and Safety of Olaparib Versus Enzalutamide or Abiraterone Acetate in Chinese Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations (PROfound-CN)

AstraZeneca·interventional·Posted Jul 13, 2022·Updated Apr 21, 2026

In Brief

A Phase 4 clinical trial evaluating olaparib, enzalutamide, and 2 other interventions for Metastatic Castration-resistant Prostate Cancer. Active but no longer recruiting, targeting 43 participants across 35 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have BRCA1/2 mutations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Castration-resistant Prostate Cancer
CountriesChina
CollaboratorsMerck Sharp & Dohme LLC, Foundation Medicine, Myriad Genetics, Inc.

Timeline

Phase 4Active
20232024202520262027
First PostedJul 13, 2022
Enrollment StartJul 29, 2022
Primary CompletionOct 22, 2024
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 4.0 years ago

Interventions

olaparibdrug

300 mg (2x 150 mg tablets) twice daily

enzalutamidedrug

160 mg (4 x 40 mg capsules) once daily

abiraterone acetatedrug

1,000 mg (4 x 250 mg tablets) once daily

Prednisonedrug

5mg(5mg x 1 tablet) twice daily